Delivery Order SPE2DR25D9112-SPE2DR26FDER0
- Not listed
- The Defense Logistics Agency awarded a $12,468.75 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/ml. The award, issued on January 29, 2026, with an ultimate completion date of January 30, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. This firm fixed-price delivery order, issued on January 20, 2026, with an ultimate completion date of January 21, 2026, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement....
- The Defense Logistics Agency awarded a delivery order valued at $12,468.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/ml. This firm fixed-price delivery order, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- The Defense Logistics Agency issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Fasenra pen 30 mg/ml. The award, dated January 27, 2026, is firm fixed-price with an ultimate completion date of January 28, 2026, and carries no set-aside designation. DMS Pharmaceutical Group will perform at its Park Ridge facility. This delivery order represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/ml. The delivery order, issued on January 9, 2026, with an ultimate completion date of January 12, 2026, operates under a firm fixed-price contract structure with no set-aside designation. DMS Pharmaceutical Group is performing work at its headquarters location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The award, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group...
- The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Fasenra Pen 30mg/ml. The award, issued on January 14, 2026, with an ultimate completion date of February 11, 2026, utilizes firm fixed-price pricing with no set-aside designation. DMS Pharmaceutical Group will perform the delivery from its Park Ridge facility, leveraging its...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $2,493.75 for Fasenra Pen 30 mg/ml on January 14, 2026. This firm fixed-price delivery order, issued without set-aside designation, is funded by the Defense Logistics Agency and will be performed at the contractor's Park Ridge facility, with an ultimate completion date of January 15, 2026. The award represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a $7,481.25 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra Pen 30 mg/ml. The award, issued on January 20, 2026, with an ultimate completion date of January 21, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award...
- The Defense Logistics Agency awarded a $2,493.75 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra Pen 30 mg/mL. This delivery order, issued on January 20, 2026, with an ultimate completion date of January 21, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was funded by the Defense Logistics...
- SPE2DR25D9112Indefinite Delivery Contract
- SPE2DR25D9112-SPE2DR26FDER0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The award was issued on January 29, 2026, with an ultimate completion date of January 30, 2026, under a firm fixed-price contract structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9 million contract awarded in November 2025 that positions the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations. DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, supplying an extensive portfolio of pharmaceuticals ranging from routine medications to specialty biologics and oncology treatments. The company's established performance across multiple therapeutic categories and product lines, combined with its small business status, enables it to compete effectively in federal procurement while supporting recurring medical supply needs of military healthcare facilities. The PPV-G GEN V program, structured as a 30-month base period with three 30-month option periods through December 2036, represents a broader $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical availability across the Defense Department's global medical infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 1/28/26 |